Microbot Medical (MBOT) Competitors

$0.94
-0.03 (-3.09%)
(As of 05/17/2024 ET)

MBOT vs. NXGL, SSKN, PETV, GCTK, BTCY, TTOO, PSTV, NURO, MHUA, and OSA

Should you be buying Microbot Medical stock or one of its competitors? The main competitors of Microbot Medical include NEXGEL (NXGL), STRATA Skin Sciences (SSKN), PetVivo (PETV), GlucoTrack (GCTK), Biotricity (BTCY), T2 Biosystems (TTOO), Plus Therapeutics (PSTV), NeuroMetrix (NURO), Meihua International Medical Technologies (MHUA), and ProSomnus (OSA). These companies are all part of the "surgical & medical instruments" industry.

Microbot Medical vs.

Microbot Medical (NASDAQ:MBOT) and NEXGEL (NASDAQ:NXGL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk, community ranking and dividends.

Microbot Medical has a net margin of 0.00% compared to NEXGEL's net margin of -67.48%. NEXGEL's return on equity of -54.71% beat Microbot Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Microbot MedicalN/A -144.30% -109.52%
NEXGEL -67.48%-54.71%-31.35%

16.3% of Microbot Medical shares are held by institutional investors. Comparatively, 2.2% of NEXGEL shares are held by institutional investors. 10.6% of Microbot Medical shares are held by insiders. Comparatively, 27.2% of NEXGEL shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Microbot Medical has a beta of 1.7, indicating that its stock price is 70% more volatile than the S&P 500. Comparatively, NEXGEL has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500.

Microbot Medical received 345 more outperform votes than NEXGEL when rated by MarketBeat users. Likewise, 70.61% of users gave Microbot Medical an outperform vote while only 50.00% of users gave NEXGEL an outperform vote.

CompanyUnderperformOutperform
Microbot MedicalOutperform Votes
346
70.61%
Underperform Votes
144
29.39%
NEXGELOutperform Votes
1
50.00%
Underperform Votes
1
50.00%

Microbot Medical currently has a consensus target price of $7.00, suggesting a potential upside of 644.60%. Given Microbot Medical's higher possible upside, equities research analysts plainly believe Microbot Medical is more favorable than NEXGEL.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Microbot Medical
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
NEXGEL
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

NEXGEL has higher revenue and earnings than Microbot Medical. NEXGEL is trading at a lower price-to-earnings ratio than Microbot Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Microbot MedicalN/AN/A-$10.74M-$0.89-1.06
NEXGEL$4.09M3.60-$3.16M-$0.55-4.30

In the previous week, NEXGEL had 6 more articles in the media than Microbot Medical. MarketBeat recorded 9 mentions for NEXGEL and 3 mentions for Microbot Medical. Microbot Medical's average media sentiment score of 0.64 beat NEXGEL's score of 0.42 indicating that Microbot Medical is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Microbot Medical
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
NEXGEL
2 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Microbot Medical beats NEXGEL on 9 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBOT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MBOT vs. The Competition

MetricMicrobot MedicalSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$13.54M$3.95B$5.10B$7.94B
Dividend YieldN/A1.96%37.44%3.91%
P/E Ratio-1.0615.74178.7418.78
Price / SalesN/A66.562,396.33111.81
Price / CashN/A47.4636.5632.08
Price / Book2.474.745.734.68
Net Income-$10.74M$4.53M$104.88M$217.01M
7 Day Performance1.82%2.07%1.87%2.90%
1 Month Performance5.63%3.43%4.76%6.58%
1 Year Performance-17.25%19.54%7.73%10.15%

Microbot Medical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NXGL
NEXGEL
0.6791 of 5 stars
$2.21
+0.5%
N/A+41.2%$13.76M$4.09M-3.9519Upcoming Earnings
News Coverage
Gap Up
SSKN
STRATA Skin Sciences
1.424 of 5 stars
$0.41
-2.4%
$3.80
+825.9%
-61.0%$14.66M$33.36M-1.3299Earnings Report
Stock Split
News Coverage
Gap Up
PETV
PetVivo
0 of 5 stars
$0.72
-10.6%
N/A-63.4%$12.07M$920,000.00-0.8425Gap Up
GCTK
GlucoTrack
1.0792 of 5 stars
$0.58
-23.6%
N/A+9.3%$15.55MN/A-1.576Stock Split
News Coverage
High Trading Volume
BTCY
Biotricity
0 of 5 stars
$1.20
flat
N/AN/A$11.30M$9.64M-0.8655News Coverage
Gap Up
TTOO
T2 Biosystems
0.2157 of 5 stars
$3.24
-10.7%
$3.00
-7.4%
-78.8%$17.85M$7.19M0.00113Gap Up
High Trading Volume
PSTV
Plus Therapeutics
2.5143 of 5 stars
$2.13
+6.0%
$8.00
+275.6%
-45.4%$9.12M$4.91M-0.0620Earnings Report
News Coverage
High Trading Volume
NURO
NeuroMetrix
0 of 5 stars
$4.40
flat
N/A-48.4%$8.76M$5.90M-0.7126Gap Down
MHUA
Meihua International Medical Technologies
0 of 5 stars
$0.76
+11.8%
N/A-80.0%$19.02M$97.10M0.00626Positive News
OSA
ProSomnus
1.0522 of 5 stars
N/A$2.33
+∞
-98.8%$8.18M$27.65M-0.30136Gap Down

Related Companies and Tools

This page (NASDAQ:MBOT) was last updated on 5/18/2024 by MarketBeat.com Staff

From Our Partners